Correction of Multispectral Singlet Oxygen Luminescent Dosimetry (MSOLD) for Tissue Optical Properties in Photofrin-Mediated Photodynamic Therapy.

The direct detection of singlet-state oxygen (O) constitutes the holy grail dosimetric method for type-II photodynamic therapy (PDT), a goal that can be quantified using multispectral singlet oxygen near-infrared luminescence dosimetry (MSOLD). The optical properties of tissues, specifically their scattering and absorption coefficients, play a crucial role in determining how the treatment and luminescence light are attenuated. Variations in these properties can significantly impact the spatial distribution of the treatment light and hence the generation of singlet oxygen and the detection of singlet oxygen luminescence signals.

The PH domain in the ArfGAP ASAP1 drives catalytic activation through an unprecedented allosteric mechanism.

ASAP1 is a multidomain Arf GTPase-activating protein (ArfGAP) that catalyzes GTP hydrolysis on the small GTPase Arf1 and is implicated in cancer progression. The PH domain of ASAP1 enhances its activity greater than 7 orders of magnitude but the underlying mechanisms remain poorly understood. Here, we combined Nuclear Magnetic Resonance (NMR), Molecular Dynamic (MD) simulations and mathematical modeling of functional data to build a comprehensive structural-mechanistic model of the complex of Arf1 and the ASAP1 PH domain on a membrane surface.

Predicting protein curvature sensing across membrane compositions with a bilayer continuum model.

Unlabelled: Cytoplasmic proteins must recruit to membranes to function in processes such as endocytosis and cell division. Many of these proteins recognize not only the chemical structure of the membrane lipids, but the curvature of the surface, binding more strongly to more highly curved surfaces, or 'curvature sensing'. Curvature sensing by amphipathic helices is known to vary with membrane bending rigidity, but changes to lipid composition can simultaneously alter membrane thickness, spontaneous curvature, and leaflet symmetry, thus far preventing a systematic characterization of lipid composition on such curvature sensing through either experiment or simulation.

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.